e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

28.02 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Agios Pharmaceuticals's Return On Capital Employed Overview ↗

November 17, 2022

Via Benzinga

Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients ↗

November 11, 2022

Via Benzinga

Agios Pharmaceuticals: Q3 Earnings Insights ↗

November 03, 2022

Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗

September 02, 2022

Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93.

Via Investor's Business Daily

Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday ↗

September 01, 2022

Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) jumped 48.5% to $19.90 after Novo Nordisk announced it will acquire the company for $20 per share in cash.

Via Benzinga

Looking Into Agios Pharmaceuticals Return On Capital Employed ↗

August 15, 2022

Via Benzinga

Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff ↗

May 17, 2022

Via Benzinga

7 Analysts Have This to Say About Agios Pharmaceuticals ↗

May 17, 2022

Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:

Via Benzinga

Agios Pharmaceuticals: Q1 Earnings Insights ↗

May 05, 2022

Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday ↗

September 02, 2022

Gainers

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session ↗

September 01, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split.

Via Benzinga

Agios Pharmaceuticals: Q2 Earnings Insights ↗

August 04, 2022

Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022 ↗

July 27, 2022

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program ↗

July 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

U.S. Stock Futures Higher; All Eyes On Inflation Data ↗

July 13, 2022

Pre-open movers

Via Benzinga

Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday ↗

July 13, 2022

With the US stock futures trading slightly higher this morning on Wednesday after recording losses in the previous session, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 27, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates ↗

March 02, 2022

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Analyst Ratings For Agios Pharmaceuticals ↗

February 22, 2022

Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

What 4 Analyst Ratings Have To Say About Agios Pharmaceuticals ↗

February 22, 2022

Within the last quarter, Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings ↗

February 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...

Via Benzinga

FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder ↗

February 18, 2022

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate...

Via Benzinga

The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios ↗

February 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...

Via Benzinga

3 Desirable Drug Stocks With Very Promising Pipelines ↗

February 16, 2022

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

Via InvestorPlace

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate...

Via Talk Markets

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy